Lantern Pharma is trading 10.16% down at $0.73 on October 12, 2026, in an unexplained stock-specific move. - No clear company-specific announcement explaining the decline has been identified. - Latest company news was Taiwan approval to advance the Phase 2 HARMONIC trial, announced October 7; a scheduled investor presentation is October 15. Neither is a new catalyst for the drop. - The broader market is mixed, with no same-direction decline greater than 0.5% clearly explaining the move; no confirmed company, sector, or market catalyst has been identified.